| Company Contact: | Investor Relations Contact: |
| Mr. Y. Tristan Kuo | Mr. Crocker Coulson |
| CFO | President |
| China Biologic Products, Inc. | CCG Investor Relations |
| Tel: +86-538- 6202206 | Tel: +1-646-213-1915 (NY office) |
| Email: IR@chinabiologic.com | Email: crocker.coulson@ccgir.com |
| www.chinabiologic.com | www.ccgir.com |
For Immediate Release
China Biologic Products Reports Second Quarter 2008 Results
Taian City, Shandong Province, PRC – August 14, 2008 – China Biologic Products, Inc. (CBPO.OB) ("China Biologic," the "Company"), one of the leading plasma-based pharmaceutical companies in the People’s Republic of China ("PRC"), today reported financial results for the second quarter ended June 30, 2008.
Second Quarter 2008 Highlights
Revenues increased 35.1% year-over-year to $11.9 million
Gross profit increased 36.4% to $8.3 million over the second quarter 2007
Gross margin improved to 69.5%, from 68.8% for the same period last year
Operating income totaled $5.0 million, down 1.5% from the previous year
Net income totaled $2.0 million, or $0.09 per diluted share
Non-GAAP net income was $3.3 million, a 4.2% decline over 2007, or $0.15 per diluted share*
* Excludes Stock Based Compensation ("SBC"). See Table 1 for a reconciliation of Net Income and EPS to exclude SBC.
"We are pleased to report solid revenue and profitability in the second quarter, primarily due to strong demand and price increases for our plasma based products," said Mr. Chao Ming Zhao, CEO of China Biologic Products, "During the quarter, we received approvals from the SFDA to produce Cryoprecipitate and to conduct clinical trials of Human Prothrombin Complex. We are now one of the few producers offering the widest range of Human Albumin products available in China. We also received approval during the period to set up a new plasma collection station in Guangxi Province due to the relocation of our Fang Cheng Plasma Collection Station, which represents a significant milestone for our Company and further secures our plasma supply."
During the quarter, the Company achieved the following milestones:
Received approval for the production of Cryoprecipitate and clinical trials of Human Prothrombin Complex
Began production and sales of Human Albumin 12.5g/vial (25%, 50 ml)
Received approval to purchase excess clinical plasma
Received approval to set up a new plasma collection station in Pu Bei County, Guangxi Province to replace its Fang Cheng Plasma Collection Station
1
Second Quarter 2008 Results
Revenues for the second quarter of 2008 were $11.9 million, up 35.1% compared to $8.8 million for the same period of 2007. The increase in revenues is primarily attributable to a general increase in prices of plasma based products together with foreign exchange translation benefits. During the second quarter, plasma based products experienced a price increase of approximately 51.2%, weighted average, period to period, which was offset by a decrease in the sales volume by four of the Company’s products, including human albumin. The decrease in sales volume is due primarily to the Company stockpiling inventory to meet the expected demand for its products during its month-long maintenance shut-down that commenced in late July.
Gross profit was up 36.4% to $8.3 million, while the gross margin was 69.5% for the second quarter of 2008, compared with approximately $6.1 million and 68.8% in the second quarter of 2007, respectively. The 0.7% increase in gross margin was mainly due to the increased sales of higher margin products.
Total operating expenses for the second quarter of 2008 were $3.3 million, or 27.8% of revenue, up 221.2% from the same period in 2007. Selling expenses increased 149.2% to $0.51 million. The increase in selling expense is primarily due to the increase in compensation for sales personnel as the company restructured its employee compensation companywide. General and administrative ("G&A") expenses were $1.3 million or 10.6% of revenue, an increase of 67.3% from the same period last year. The increase in G&A is mainly due to the increase in personnel cost, auditing, and legal fees and costs associated with increased investor relation activities. A non-cash employee compensation expense of $1.3 million was created by the Company’s adoption of the 2008 Equity Incentive Plan on May 2008. Research and development expenses increased 290.1% to $0.28 million, or 2.3% of revenues, compared to 0.8% of revenues in the same period last year. The dollar and percentage increase was primarily due to the increase in research activities and clinical trials of the Company’s new products.
As a result of the increase in operating expenses, income from operations decreased 1.5% to $5.0 million during the second quarter of 2008, representing an operating margin of 41.7%, as compared to $5.0 million and 57.1% in the same period 2007.
Provision for income taxes increased 150.2% year over year to $2.1 million. The Company provisioned its income tax for the second quarter of 2008 at the new PRC corporate income tax rate of 25%, as compared with the 15% preferential tax rate during the fiscal year 2007. The Company is in the process of applying for status as a new or high technology company in order to qualify for the favorable tax rate of 15%.
Net income for the second quarter of 2008 decreased 40.9% year over year, to $2.0 million or $0.09 per fully diluted share. Net margin during the period was 17.1%, compared to 39.0% in the same quarter last year. The decrease in net income was materially impacted by a one-time non-cash employee compensation recognized pursuant to SFAS 123(R), and by the negative effect of China’s newly-implemented Unified Corporate Income Tax Law on the Company’s enterprise income tax.
Non-GAAP net income in the second quarter of 2008 was $3.3 million or $0.15 per fully diluted share, a 4.2% decrease from non-GAAP net income of $3.4 million, or $0.16 per fully diluted share in the second quarter of 2007.*
* Excludes Stock Based Compensation ("SBC"). See Table 1 for a reconciliation of Net Income and EPS to exclude SBC.
2
Six Months Results
For the first six months of 2008, total revenue was $19.8 million, up 19.8% from the first six months of 2007. Gross profit for the first six months of 2008 was $14.2 million, up 35.2% from $10.5 million in the comparable period a year ago. Gross margin was 71.7% compared to 63.6% for the first six month of 2008 and 2007, respectively. Income from operations for the period was $8.6 million, up 9.4% from $7.8 million in the first six months of 2007. Net income for the first six months of 2008 was $4.3 million, down 19.5% from $5.3 million in the first six months of 2007. Fully diluted earnings per share were $0.20 for the first six months of 2008 compared to $0.25 in the first six months of 2007. The six-month net income was impacted by non cash employee compensation and the newly-implemented PRC enterprise income tax law.
Financial Condition
As of June 30, 2008, the Company had $8.8 million in cash, approximately $14.3 million in working capital and a current ratio of 2.5. Shareholder’s equity at the end of the second quarter of 2008 stood at $29.8 million compared to $22.4 million at the end of 2007.
Recent Developments
(1) The Company began operation of its newly constructed plasma collection station in Qi He County, Shandong Province.
(2) The Company was honored with the Advanced Technology Certification for Foreign-Funded Enterprises.
(3) On July 24, 2008, the Board of Directors of the Company appointed Mr. Sean Shao, Dr. Jie Gan, and Dr. Tong-Jun Lin to serve on the Board as "independent directors" of the Company (the "Independent Directors"), as that term is defined by Rule 4200(a)(15) of the Marketplace Rules of The Nasdaq Stock Market, Inc. On the same date, the Board also established the Audit Committee, with all three Independent Directors as the members, and adopted the Audit Committee Charter. Mr. Sean Shao was appointed as the Chair of the Audit Committee.
(4) The Company began annual maintenance of its production facilities on July 25, 2008. The maintenance period will last for one month. During the required maintenance period, the Company will conduct any required major maintenance of its production equipment to ensure the efficiency and safety of subsequent production. The Company will also take advantage of the maintenance period to train its staff, and allow them to take proper vacation time as required by Chinese labor laws. The Company has sufficient product inventories on hand to meet market demand during the maintenance period. In addition, operation of the Company’s plasma collection stations will continue as usual to ensure that the manufacturing facilities can resume their normal operations at the end of the maintenance period.
(5) On August 7, 2008, the Board of Directors of the Company established a Governance and Nominating Committee and a Compensation Committee and appointed each of the Company’s Independent Directors to each committee. Dr. Lin was appointed to serve as the Chair of the Governance and Nominating Committee and Dr. Gan was appointed to serve as the Chair of the Compensation Committee.
3
Business Outlook
For the most recent quarter, the Company received SFDA approval in a variety of plasma-based products including the approval to supply Cryoprecipitate to Green Cross China for the use in the production of Human Coagulation Factor VIII, an effort that leads the Company to focus on research and development of Human Coagulation Factor VIII. The Company also received approval to commence clinical trial of its new Human Prothrombin Complex for the production and sale of human albumin 12.5g/vial 925%, 50ml). The Company is currently one of the few producers offering the widest range of Human Albumin products available in the Chinese market. Management believes that these approvals are a reflection of the Company’s R&D efforts to upgrade its product portfolio.
Realizing that the supply of human plasma is one of the keys to success in the industry, the Company sought and obtained approval to relocate its Fang Cheng plasma collection station to Pu Bei County, Guangxi Province, in an effort to increase collection volumes. The Company also began operations at its newly constructed Qi He station in July, which is expected to greatly expand the Company’s plasma supply. The station has the capacity to collect human plasma from 1,000 donors daily, the equivalent of 100 metric tons of plasma supply annually.
The Company began the annual maintenance of its production facilities on July 25, 2008. The maintenance period is expected to last for one month, during which production at the Company’s manufacturing facilities will be suspended. Annual maintenance allows the Company to conduct any required major maintenance of its production facilities and equipment to ensure the efficiency and safety of subsequent production. The Company has sufficient product inventories on hand to meet customer demands during the maintenance period. In addition, operation of the Company’s plasma collection stations will continue as usual to ensure that the manufacturing facilities can resume their normal operations at the end of the maintenance period.
Commencing July 1, 2008, the PRC government imposed a new measure setting the quarantine period for blood plasma used as materials for blood products. This new measure required all blood plasma used to make blood products to be placed in quarantine for a 90-day period, after which time the donors of such plasma will be required to take a second screening test before the plasma can be put into production. In preparation for this new measure, the Company stocked its plasma inventory during the second quarter and is expected to have sufficient supplies when its production facilities reopen in late August 2008. In addition, during the second quarter, the Company increased its inventory of finished goods in order to meet the anticipated needs of its customers during the third quarter of 2008.
The foregoing measure as well as the continued restriction on the importation of foreign plasma based products have placed pressure on the already tightened supply of plasma available for production. In addition, the overall effect of these and other regulations has been to reduce competition and increase the barriers to entry. In order to maintain its favorable position in the industry, the Company is focusing on its research and development efforts on securing plasma supply and on the development and production of new high quality plasma-based products.
"We are pleased with our operational results given the government’s restriction on both the supply of human plasma and the slow approval process of the plasma-based products for sale earlier in the year," remarked Mr. Zhao. "Now that the government approval process for plasma based finished goods has returned to more normal levels, we are optimistic about our outlook for the remainder of the year. We have made great efforts to secure raw material inventories and finished products in order to better serve our customers."
4
*TABLE 1
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2008 AND 2007
Adjusted Net Income | Three Months Ended June 30, 2008 | Three Months Ended June 30, 2007 |
Net Income (Loss) Diluted EPS | Net Income | Diluted EPS | Net Income | Diluted EPS |
Adjusted Amount - Non GAAP | $3,297,342 | $0.15 | $3,443,500 | $0.16 |
Non-cash employee compensation (1) | $1,263,188 | $0.06 | - | - |
Amount per consolidated statement of operations | $2,034,154 | $0.09 | $3,443,500 | $0.16 |
| | | | |
| | | | |
Adjusted Net Income | Six Months Ended June 30, 2008 | Six Months Ended June 30, 2007 |
Net Income (Loss) Diluted EPS | Net Income | Diluted EPS | Net Income | Diluted EPS |
Adjusted Amount - Non GAAP | $5,565,142 | $0.26 | $5,342,343 | $0.25 |
Non-cash employee compensation (1) | $1,263,188 | $0.06 | - | - |
Amount per consolidated statement of operations | $4,301,954 | $0.20 | $5,342,343 | $0.25 |
(1) Non-cash compensation expense of $1,263,188 in connection with adoption of the equity incentive plan granting share options on the Company's common stock to employees and directors
Use of Non-GAAP Financial Measures
GAAP results for the three months ended June 30, 2008 include non-cash stock based compensation charges. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of this item in this release. The Company's management believes that this non-GAAP measure provides investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this press release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiary Shandong Taibang, is currently the only plasma-based biopharmaceutical company approved by the government of Shandong Province, the second largest province with a population of 93 million. The company is engaged primarily in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Plasma-based Human Albumin is used mainly to increase blood volume while Immunoglobulin is used for disease prevention and treatment.
5
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
--FINANCIAL TABLES FOLLOW--
6
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME
FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2008 AND 2007
(Unaudited)
| | | Three months ended June 30, | | Six months ended June 30, |
| | | 2008 | | 2007 | | 2008 | | 2007 |
| | | | | | | | | |
| REVENUES | $ | 11,925,842 | $ | 8,826,059 | $ | 19,774,849 | $ | 16,503,911 |
| | | | | | | | | |
| COST OF SALES | | 3,638,128 | | 2,750,972 | | 5,587,026 | | 6,012,348 |
| | | | | | | | | |
| GROSS PROFIT | | 8,287,714 | | 6,075,087 | | 14,187,823 | | 10,491,563 |
| | | | | | | | | |
| OPERATING EXPENSES | | | | | | | | |
Selling expenses | | 510,565 | | 204,855 | | 1,005,094 | | 702,468 |
General and administrative expenses | | 1,266,592 | | 757,016 | | 2,858,666 | | 1,708,341 |
Research and development expenses | | 279,833 | | 71,728 | | 463,615 | | 221,635 |
Compensation expense | | 1,263,188 | | | | 1,263,188 | | |
| TOTAL OPERATING EXPENSES | | 3,320,178 | | 1,033,599 | | 5,590,563 | | 2,632,444 |
| | | | | | | | | |
| INCOME FROM OPERATIONS | | 4,967,536 | | 5,041,488 | | 8,597,260 | | 7,859,119 |
| | | | | | | | | |
| OTHER EXPENSES | | | | | | | | |
Interest income | | (19,601) | | (4,386) | | (30,490) | | (17,113) |
Interest expense | | 18,755 | | 18,692 | | 44,672 | | 63,337 |
Other income | | (364) | | (23) | | (567) | | (4,093) |
Other expense | | 52,405 | | 15,400 | | 53,019 | | 27,135 |
| TOTAL OTHER EXPENSES | | 51,195 | | 29,683 | | 66,634 | | 69,266 |
| | | | | | | | | |
| INCOME BEFORE PROVISION FOR INCOME TAXES | | | | | | | | |
| AND MINORITY INTEREST | | 4,916,341 | | 5,011,805 | | 8,530,626 | | 7,789,853 |
| | | | | | | | | |
| PROVISION FOR INCOME TAXES | | 2,123,843 | | 848,852 | | 2,864,325 | | 1,298,962 |
| | | | | | | | | |
| NET INCOME BEFORE MINORITY INTEREST | | 2,792,498 | | 4,162,953 | | 5,666,301 | | 6,490,891 |
| | | | | | | | | |
| LESS MINORITY INTEREST | | 758,344 | | 719,453 | | 1,364,347 | | 1,148,548 |
| | | | | | | | | |
| NET INCOME | | 2,034,154 | | 3,443,500 | | 4,301,954 | | 5,342,343 |
| | | | | | | | | |
| FOREIGN CURRENCY TRANSLATION GAIN | | 747,767 | | 370,319 | | 1,871,125 | | 463,092 |
| | | | | | | | | |
| OTHER COMPREHENSIVE INCOME | $ | 2,781,921 | $ | 3,813,819 | $ | 6,173,079 | $ | 5,805,435 |
| | | | | | | | | |
| BASIC EARNINGS PER SHARE | | | | | | | | |
Weighted average number of shares | | 21,434,942 | | 21,434,942 | | 21,434,942 | | 21,434,942 |
Earnings per share | $ | 0.09 | $ | 0.16 | $ | 0.20 | $ | 0.25 |
| | | | | | | | | |
| DILUTED EARNINGS PER SHARE | | | | | | | | |
Weighted average number of shares | | 21,664,429 | | 21,434,942 | | 21,808,852 | | 21,434,942 |
Earnings per share | $ | 0.09 | $ | 0.16 | $ | 0.20 | $ | 0.25 |
7
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AS OF JUNE 30, 2008 AND DECEMBER 31, 2007
ASSETS
| | | June 30, | | December 31, |
| | | 2008 | | 2007 |
| | | (Unaudited) | | |
| CURRENT ASSETS: | | | | |
Cash | $ | 8,775,242 | $ | 5,010,033 |
Accounts receivable, net of allowance for doubtful accounts of $1,202,838 | | | | |
and $1,238,772 as of June 30, 2008 and December 31, 2007, respectively | | 939,406 | | 316,869 |
Notes receivable | | 68,142 | | 41,130 |
Other receivables | | 659,799 | | 425,163 |
Other receivable- related party | | 307,481 | | 290,307 |
Inventories | | 12,759,906 | | 9,505,074 |
Prepayments and deferred expense | | 395,949 | | 138,756 |
Total current assets | | 23,905,925 | | 15,727,332 |
| | | | | |
| PLANT AND EQUIPMENT, net | | 18,132,745 | | 15,434,124 |
| | | �� | | |
| OTHER ASSETS: | | | | |
Advances on equipment purchases | | 791,014 | | 711,459 |
Long term prepayment - related party | | 549,605 | | 516,456 |
Intangible assets, net | | 929,738 | | 915,874 |
Total other assets | | 2,270,357 | | 2,143,789 |
| | | | |
Total assets | $ | 44,309,027 | $ | 33,305,245 |
| | | | | |
LIABILITIES AND SHAREHOLDERS' EQUITY |
| | | | | |
| CURRENT LIABILITIES: | | | | |
Accounts payable | $ | 2,546,739 | $ | 2,677,587 |
Short term loans - bank | | - | | 685,500 |
Short term loan - minority shareholder | | 769,060 | | 722,674 |
Other payables and accrued liabilities | | 1,980,188 | | 1,200,068 |
Other payable - land use right | | 324,411 | | 305,571 |
Dividend payable | | 643,842 | | 506,626 |
Customer deposits | | 696,966 | | 398,794 |
Taxes payable | | 2,604,880 | | 384,788 |
Total current liabilities | | 9,566,086 | | 6,881,608 |
| | | | | |
| COMMITMENT AND CONTINGENCIES | | 40,899 | | 142,120 |
| | | | | |
| MINORITY INTEREST | | 4,870,150 | | 3,885,892 |
| | | | | |
| SHAREHOLDERS' EQUITY: | | | | |
Common stock, $0.0001 par value, 100,000,000 shares authorized, 21,434,942 | | | | |
shares issued and outstanding at June 30, 2008 and December 31, 2007, respectively | | 2,143 | | 2,143 |
Paid-in-capital | | 10,651,493 | | 9,388,305 |
Statutory reserves | | 5,334,520 | | 4,513,077 |
Retained earnings | | 9,363,817 | | 5,883,306 |
Accumulated other comprehensive income | | 4,479,919 | | 2,608,794 |
Total shareholders' equity | | 29,831,892 | | 22,395,625 |
| | | | | |
Total liabilities and shareholders' equity | $ | 44,309,027 | $ | 33,305,245 |
8
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2008 AND 2007
(UNAUDITED)
| | | 2008 | | 2007 |
| | | | | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | | | | |
Net income | $ | 4,301,954 | $ | 5,342,343 |
Adjustments to reconcile net income to cash | | | | |
provided by operating activities: | | | | |
Recovery of bad debt previously reserved | | (107,583) | | - |
Minority Interest | | 1,364,347 | | 1,148,548 |
Depreciation | | 579,754 | | 417,406 |
Amortization | | 53,192 | | 23,686 |
Loss on disposal of equipment | | 1,900 | | 4,064 |
Stock-based compensation | | 1,263,188 | | - |
Change in operating assets and liabilities: | | | | |
Accounts receivable | | (477,858) | | 458,758 |
Notes receivable | | (23,694) | | 57,721 |
Other receivables | | (201,576) | | (1,317,291) |
Other receivables – shareholders | | 1,419 | | (146,149) |
Inventories | | (2,571,137) | | (989,274) |
Prepayments and deferred expenses | | (241,377) | | 187,928 |
Accounts payable | | (294,290) | | 36,733 |
Other payables and accrued liabilities | | 683,527 | | 298,787 |
Other payable – land use right | | (752) | | - |
Customer deposits | | 264,990 | | 1,239,099 |
Taxes payable | | 2,134,302 | | 547,273 |
Contingent liability | | (107,273) | | - |
Net cash provided by operating activities | | 6,623,033 | | 7,309,632 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | | | |
Additions to plant and equipment | | (2,245,627) | | (3,830,236) |
Additions to construction in progress | | - | | 9,393 |
Additions to intangible assets | | (9,517) | | (46,213) |
Proceeds from sale of equipment | | 3,546 | | - |
Advances on building, equipment and intangible assets purchases | | (32,945) | | (5,672) |
Net cash used in investing activities | | (2,284,543) | | (3,872,728) |
| CASH FLOWS FINANCING ACTIVITIES: | | | | |
Restricted cash | | - | | (65,750) |
Proceeds from short term loans – bank | | - | | 1,297,100 |
Payments on short term loans – bank | | (709,200) | | (2,511,400) |
Proceeds from employee loans | | - | | 752,750 |
Payments on long term debt | | - | | (194,565) |
Dividends paid to minority shareholders | | (283,680) | | (476,597) |
Net cash (used in) provided by financing activities | | (992,880) | | (1,198,462) |
| EFFECTS OF EXCHANGE RATE CHANGE IN CASH | | 419,599 | | 41,654 |
| INCREASE IN CASH | | 3,765,209 | | 2,280,096 |
| CASH, beginning of period | | 5,010,033 | | 4,268,220 |
| CASH, end of period | $ | 8,775,242 | $ | 6,548,316 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | | | | |
Income taxes paid | $ | 850,605 | $ | 743,113 |
Interest paid (net of capitalized interest) | $ | 29,901 | $ | 55,714 |
9
